
MLYS Stock Forecast & Price Target
MLYS Analyst Ratings
Bulls say
Mineralys Therapeutics Inc. is focusing on the development of lorundrostat, which demonstrates a strong potential in treating uncontrolled and resistant hypertension, showcasing a compelling placebo-adjusted blood pressure benefit exceeding 10mmHg. Recent insights from Key Opinion Leaders (KOLs) support the differentiated profile of lorundrostat, highlighting its robust effects across targeted patient populations and the anticipated positive FDA feedback leading to an NDA submission. Furthermore, there is an increased estimate of patients seeking innovative treatment, rising from 10% to 12% among diagnosed uncontrolled hypertension patients, indicating a growing market opportunity for lorundrostat in addressing significant unmet medical needs.
Bears say
Mineralys Therapeutics Inc faces significant risks that impact its investment outlook, particularly concerning the commercial potential of its lead product candidate, lorundrostat. The company's ability to achieve projected peak commercial revenues is hindered by uncertainties in market size, penetration rates, and pricing strategies. Additionally, the failure to secure adequate capital resources for operations and the ongoing challenges associated with program development and commercialization contribute to a negative financial outlook for the company.
This aggregate rating is based on analysts' research of Mineralys Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
MLYS Analyst Forecast & Price Prediction
Start investing in MLYS
Order type
Buy in
Order amount
Est. shares
0 shares